<DOC>
	<DOCNO>NCT00418847</DOCNO>
	<brief_summary>The purpose study investigate pharmacokinetics Zavesca ( miglustat , OGT918 ) give single multiple dos juvenile patient GM2 gangliosidosis .</brief_summary>
	<brief_title>Pharmacokinetics Tolerability Zavesca® ( Miglustat ) In Patients With Juvenile GM2 Gangliosidosis</brief_title>
	<detailed_description>The GM2 gangliosidoses group neuro-degenerative lysosomal storage disease result accumulation GM2 related glycolipids central nervous system ( CNS ) . Tay-Sachs Sandhoff disease two variant indistinguishable clinical ground . According onset rate disease progression , condition categorize infantile , juvenile adult form . This open-label , single-arm study design ass pharmacokinetics , safety tolerability miglustat juvenile patient . Miglustat administer maximum dose 600 mg/day , divide three dos per day . The dose use patient pediatric age range relate patient 's body surface area . The pharmacokinetics assessment study perform in-hospital 24 hour period , take place day one month 3 visit . The clinical ( include safety tolerability ) assessments perform throughout 24-month study period .</detailed_description>
	<mesh_term>Gangliosidoses</mesh_term>
	<mesh_term>Gangliosidoses , GM2</mesh_term>
	<mesh_term>Tay-Sachs Disease</mesh_term>
	<mesh_term>Miglustat</mesh_term>
	<mesh_term>1-Deoxynojirimycin</mesh_term>
	<criteria>Diagnosis GM2 gangliosidosis confirm demonstration profound deficiency βhexosaminidase A A &amp; B peripheral blood leukocyte culture skin fibroblast Aged 6 20 year Onset characteristic clinical symptom disease age 15 year Normal renal hepatic function Fertile patient agree use adequate contraception throughout study 3 month cessation miglustat treatment . Patients tolerate study procedure , compliant therapy unable travel study center require protocol . Patients receive investigational agent within 3 month study initiation . Patients disease may affect absorption elimination drug . Patients suffer clinically significant diarrhea ( &gt; 3 liquid stool per day &gt; 7 day ) without definable cause within 3 month baseline visit , history significant gastrointestinal disorder . Patients swallow difficulty . Patients high probability die study . Patients opinion investigator ( whatever reason ) think unsuitable study .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>pediatrics</keyword>
	<keyword>lysosomal storage disease</keyword>
	<keyword>Gangliosidoses GM2</keyword>
	<keyword>Tay-Sachs disease</keyword>
	<keyword>Sandhoff disease</keyword>
	<keyword>Infantile GM2-activator deficiency</keyword>
	<keyword>Miglustat</keyword>
</DOC>